WuXi Biologics, Sinorda Partner on Bispecific Antibody for IBD
WuXi Biologics , a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IB…
